Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA.
Neuropsychopharmacology. 2011 Nov;36(12):2452-9. doi: 10.1038/npp.2011.132. Epub 2011 Jul 27.
Serum levels of inflammatory cytokines, for example, tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and IL-1 beta (IL-1β), are elevated in subjects with major depressive disorder (MDD). The reason why this occurs is unclear. Elevated levels of inflammatory cytokines could be a result of brain dysfunction in MDD. It is also possible that inflammatory cytokines contribute to depressive symptoms in MDD. If the first assumption is correct, one would expect levels to normalize with resolution of the depressive episode after treatment. Several studies have measured changes in cytokine levels during antidepressant treatment; however, the results vary. The purpose of this study was to pool all available data on changes in serum levels of TNFα, IL-6, and IL-1β during antidepressant treatment to determine whether these levels change. Studies were included if they used an approved pharmacological treatment for depression, patients had a diagnosis of MDD, and serum levels of TNFα, IL-6, and/or IL-1β were measured before and after treatment. Twenty-two studies fulfilled these criteria. Meta-analysis of these studies showed that, overall, while pharmacological antidepressant treatment reduced depressive symptoms, it did not reduce serum levels of TNFα. On the other hand, antidepressant treatment did reduce levels of IL-1β and possibly those of IL-6. Stratified subgroup analysis by class of antidepressant indicated that serotonin reuptake inhibitors may reduce levels of IL-6 and TNFα. Other antidepressants, while efficacious for depressive symptoms, did not appear to reduce cytokine levels. These results argue against the notion that resolution of a depressive episode is associated with normalization of levels of circulating inflammatory cytokines; however, the results are consistent with the possibility that inflammatory cytokines contribute to depressive symptoms and that antidepressants block the effects of inflammatory cytokines on the brain.
血清中炎症细胞因子的水平,例如肿瘤坏死因子-α(TNFα)、白细胞介素-6(IL-6)和白细胞介素-1β(IL-1β),在患有重度抑郁症(MDD)的患者中升高。发生这种情况的原因尚不清楚。炎症细胞因子水平升高可能是 MDD 大脑功能障碍的结果。也有可能炎症细胞因子导致 MDD 中的抑郁症状。如果第一种假设是正确的,人们会期望在治疗后抑郁发作缓解时水平恢复正常。一些研究已经测量了抗抑郁治疗过程中细胞因子水平的变化;然而,结果各不相同。本研究的目的是汇集所有关于抗抑郁治疗期间血清 TNFα、IL-6 和 IL-1β 水平变化的可用数据,以确定这些水平是否发生变化。如果研究使用了已批准的治疗抑郁症的药物治疗、患者被诊断为 MDD 并且在治疗前后测量了血清 TNFα、IL-6 和/或 IL-1β 水平,则将其纳入研究。有 22 项研究符合这些标准。对这些研究的荟萃分析表明,总体而言,虽然药物抗抑郁治疗可减轻抑郁症状,但它并未降低 TNFα 的血清水平。另一方面,抗抑郁治疗确实降低了 IL-1β 的水平,可能也降低了 IL-6 的水平。按抗抑郁药类别进行的分层亚组分析表明,选择性 5-羟色胺再摄取抑制剂可能会降低 IL-6 和 TNFα 的水平。其他抗抑郁药虽然对抑郁症状有效,但似乎并未降低细胞因子水平。这些结果反对这样一种观点,即抑郁发作的缓解与循环炎症细胞因子水平的正常化有关;然而,这些结果与炎症细胞因子可能导致抑郁症状以及抗抑郁药阻断炎症细胞因子对大脑的影响的可能性一致。